The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

INTRODUCTION: Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA‐approved recombinant activated human factor VII BPA for the treatment and control of bleeding in haemophilia A or B patients with inhibitors (≥12 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Miguel, Castaman, Giancarlo, Boix, Santiago Bonanad, Callaghan, Michael, de Moerloose, Philippe, Ducore, Jonathan, Hermans, Cédric, Journeycake, Janna, Leissinger, Cindy, Luck, James, Mahlangu, Johnny, Miesbach, Wolfgang, Mitha, Ismail Haroon, Négrier, Claude, Quon, Doris, Recht, Michael, Schved, Jean François, Shapiro, Amy D., Sidonio, Robert, Srivastava, Alok, Stasyshyn, Oleksandra, Vilchevska, Kateryna V., Wang, Michael, Young, Guy, Alexander, W. Allan, Al‐Sabbagh, Ahmad, Bonzo, Daniel, Macie, Christopher, Wilkinson, Thomas A., Kessler, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292935/
https://www.ncbi.nlm.nih.gov/pubmed/34636112
http://dx.doi.org/10.1111/hae.14419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292935/
https://www.ncbi.nlm.nih.gov/pubmed/34636112
http://dx.doi.org/10.1111/hae.14419

Ejemplares similares